Therapy options in cutaneous T-cell lymphoma

Narin Apisarnthanarax, Madeleine Duvic

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

The treatment of cutaneous T-cell lymphoma (CTCL) is continually evolving, as new and emerging drugs are added to the growing arsenal of CTCL therapy. The availability of newly approved investigational therapies, such as bexarotene, denileukin diftitox (DAB389-IL2), monoclonal antibodies and novel chemotherapeutic agents, adds complexity to decisions on the management and treatment of CTCL patients. In formulating a treatment plan, therapeutic options are best approached through consideration of overall clinical staging (stage IA-IVB) and skin staging (T1-T4), which affect prognosis and the characteristics of each individual patient's disease. This article will present and discuss the optimal therapeutic agents for all clinical stages of CTCL patients, based on currently available and investigational agents.

Original languageEnglish (US)
Pages (from-to)403-420
Number of pages18
JournalExpert review of anticancer therapy
Volume1
Issue number3
DOIs
StatePublished - 2001

Keywords

  • Bexatrotene
  • Chemotherapy
  • Cutaneous T-cell lymphoma
  • Demileukin diftitox
  • Electron beam therapy
  • Interferon
  • Monoclonal antibodies
  • Mycosis fungoides
  • Photopheresis
  • Phototherapy
  • Retinoids
  • Sezary syndrome

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Therapy options in cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

Cite this